Expression and functions of transient receptor potential channels in liver diseases.
10.1016/j.apsb.2022.09.005
- Author:
Wenhui WANG
1
;
Pengyu LIU
2
;
Yalin ZHANG
3
;
Li YAN
3
;
Michael X ZHU
4
;
Jin WANG
3
;
Ye YU
3
Author Information
1. Department of Pharmacology, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
2. Department of Medical Genetics and Developmental Biology, School of Medicine, the Key Laboratory of Developmental Genes and Human Diseases, Ministry of Education, Southeast University, Nanjing 210009, China.
3. School of Basic Medicine and Clinical Pharmacy and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.
4. Department of Integrative Biology and Pharmacology, McGovern Medical School, the University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
- Publication Type:Review
- Keywords:
ALD;
Fibrosis;
HCC;
Inflammation;
Liver disease;
Liver injury;
NAFLD;
TRP
- From:
Acta Pharmaceutica Sinica B
2023;13(2):445-459
- CountryChina
- Language:English
-
Abstract:
Liver diseases constitute a major healthcare burden globally, including acute hepatic injury resulted from acetaminophen overdose, ischemia-reperfusion or hepatotropic viral infection and chronic hepatitis, alcoholic liver disease (ALD), non-alcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma (HCC). Attainable treatment strategies for most liver diseases remain inadequate, highlighting the importance of substantial pathogenesis. The transient receptor potential (TRP) channels represent a versatile signalling mechanism regulating fundamental physiological processes in the liver. It is not surprising that liver diseases become a newly explored field to enrich our knowledge of TRP channels. Here, we discuss recent findings revealing TRP functions across the fundamental pathological course from early hepatocellular injury caused by various insults, to inflammation, subsequent fibrosis and hepatoma. We also explore expression levels of TRPs in liver tissues of ALD, NAFLD and HCC patients from Gene Expression Omnibus (GEO) or The Cancer Genome Atlas (TCGA) database and survival analysis estimated by Kaplan-Meier Plotter. At last, we address the therapeutical potential and challenges by pharmacologically targeting TRPs to treat liver diseases. The aim is to provide a better understanding of the implications of TRP channels in liver diseases, contributing to the discovery of novel therapeutic targets and efficient drugs.
